Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.03), $0.16 worse than the analyst estimate of ($0.87).

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Lumexa Imaging Holdings, Inc. (LMRI) Reports In-Line Q2 EPS; Offers Guidance
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c